ACADIA Pharmaceuticals 대차 대조표 상태
재무 상태 기준 확인 6/6
ACADIA Pharmaceuticals 의 총 주주 지분은 $516.7M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $914.1M 및 $397.4M 입니다. ACADIA Pharmaceuticals 의 EBIT는 $22.8M 이며 이자보상배율은 -1.1 입니다. $500.9M 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보
0%
부채 비율
US$0
부채
| 이자 보상 비율 | -1.1x |
| 현금 | US$500.94m |
| 주식 | US$516.70m |
| 총 부채 | US$397.40m |
| 총 자산 | US$914.10m |
최근 재무 상태 업데이트
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Recent updates
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Aug 26The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Aug 14ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Aug 01Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome
Jul 18FDA AdComm Rejects Nuplazid This Time But Acadia's Race Isn't Run Yet
Jun 29재무 상태 분석
단기부채: ACAD 의 단기 자산 ( $728.9M )이 단기 부채( $337.9M ).
장기 부채: ACAD 의 단기 자산( $728.9M )이 장기 부채( $59.5M ).
부채 대 자본 내역 및 분석
부채 수준: ACAD 부채가 없습니다.
부채 감소: ACAD 지난 5년간 부채가 없습니다.
부채 범위: ACAD 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.
이자 보장: ACAD 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.